Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Narazaciclib by Traws Pharma for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval
Narazaciclib is under clinical development by Traws Pharma and currently in Phase I for Human Epidermal Growth Factor Receptor 2...
Narazaciclib by Traws Pharma for Colorectal Cancer: Likelihood of Approval
Narazaciclib is under clinical development by Traws Pharma and currently in Phase I for Colorectal Cancer. According to GlobalData, Phase...
Narazaciclib by Traws Pharma for Endometrial Cancer: Likelihood of Approval
Narazaciclib is under clinical development by Traws Pharma and currently in Phase II for Endometrial Cancer. According to GlobalData, Phase...